R&D channel feed – Endpoints News

R&D channel feed

DBV shares are crushed — while rival Aimmune soars — after PhIII flop for peanut allergy med

8 years ago

Novartis partner Durect registers a PhIII pain drug flop, biotech’s shares crater

8 years ago

Buzz: Will Brent Saunders split up Allergan if he loses the Restasis patent fight?

8 years ago

Seattle's Universal Cells brings Astellas into its fold of off-the-shelf cell therapy partners

8 years ago

After some painful R&D setbacks, J&J partners with Arcturus on a shot at a hep B cure  — shares rocket up

8 years ago

In a PhIII showdown with Spark, uniQure switches out its lead gene therapy for hemophilia B

8 years ago

Sean Parker’s cancer institute keeps growing with some “mind blowing” new research projects

8 years ago

Hunting an early FDA OK, Ignyta surges on promising snapshot of lung cancer data

8 years ago

J&J is jettisoning two of its promised blockbuster drugs, and it couldn't come at a worse time

8 years ago

After getting skunked by rivals, Pfizer touts ‘breakthrough’ cancer drug lorlatinib, heads to the FDA

8 years ago

Racing against Alnylam, Ionis posts positive PhIII ATTR efficacy numbers, but questions linger

8 years ago

That $1.25B Bristol-Myers IDO1 drug? Incyte claims a former staffer stole it

8 years ago

Ionis launches an early-stage tau drug study for Alzheimer’s, picking up $10M from Biogen

8 years ago

NIH allies with 11 top cancer biopharma players in $215M drive to explore biomarkers, speed R&D

8 years ago

Positive PhIII can't salvage Merck's anacetrapib, now relegated to the scrap heap

8 years ago

Battered by mixed PhIII data, Trevena axes R&D staff and hunkers down around lead pain drug

8 years ago

Ardelyx steps up with a better round of PhIII data to compare with rivals at Ironwood, Synergy

8 years ago

Shooting for PhIII, Spero tees up a new lead antibiotic in-licensed cheap as it lines up $86M IPO

8 years ago

With just a little encouragement, biotech investors are ready to fall in love again

8 years ago

AbbVie jumps on the oncolytics bandwagon, embracing Turnstone in new collaboration

8 years ago

Eli Lilly concedes a PhIII flop for abemaciclib as breakout strategy flounders

8 years ago

Biotech scientist/entrepreneur Saurabh Saha makes an unusual return to the arms of a big — and excessively discreet — R&D group

8 years ago

'Going big': Merck launches frontline PhIII lung cancer study for Keytruda/Yervoy combo

8 years ago

In a setback, Bayer, J&J say their big PhIII secondary stroke trial for Xarelto failed

8 years ago

First page Previous page 288 289 290291292 293 294 Next page Last page